PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17047492-10	2006	Among 155 participants who received efavirenz without nelfinavir, virologic failure was associated with a two-locus interaction between ABCB1 2677G>T and CYP2B6 516G>T (65% accuracy, P<0.001).	efavirenz	36-45	ATP binding cassette subfamily B member 1	Homo sapiens	136-141	
23082557-3	2012	The present study examined the influence of ABCB-1 polymorphisms on plasma nevirapine and efavirenz levels when co-administered with rifampicin in 124 HIV/TB patients who received nevirapine- (400 mg/day) (n = 59) and efavirenz- (600 mg/day) (n = 65) based ART.	efavirenz	90-99	ATP binding cassette subfamily B member 1	Homo sapiens	44-50	
15718846-0	2005	The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism.	efavirenz	4-13	ATP binding cassette subfamily B member 1	Homo sapiens	71-98	
15718846-1	2005	Efavirenz treatment has been associated with increases in HDL-cholesterol concentrations, and the circulating levels of the drug have been related to the multidrug resistance gene 1 (MDR-1) C3435T polymorphism.	efavirenz	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	183-188	
14711599-1	2003	BACKGROUND: In a retrospective study of HIV patients under antiretroviral therapy, we investigated the influence of the MDR1 genotype (C3435T) on plasma levels of lopinavir (LPV) and efavirenz (EFV).	efavirenz	194-197	ATP binding cassette subfamily B member 1	Homo sapiens	120-124	
34945777-9	2021	On multivariate analysis, CYP2B6*6 and ABCB1c.3435 C > T genotypes and low pre-treatment low-density lipoprotein (LDL) were significantly associated with higher plasma efavirenz concentration regardless of treatment duration.	efavirenz	168-177	ATP binding cassette subfamily B member 1	Homo sapiens	39-44	
34945777-11	2021	(4) Conclusion: Pre-treatment LDL cholesterol and CYP2B6*6 and ABCB1c.3435 C > T genotypes predict efavirenz plasma exposure among HIV-infected children, but treatment-duration-dependent changes in plasma efavirenz exposure due to auto-induction are not statistically significant.	efavirenz	99-108	ATP binding cassette subfamily B member 1	Homo sapiens	63-68	
32838647-5	2020	CYP2B6 516G>T, 785A>G, 18492C>T and ABCB1 3435C>T T/C were associated with higher efavirenz plasma levels in the standard but not the lower-dose group.	efavirenz	82-91	ATP binding cassette subfamily B member 1	Homo sapiens	36-41	
31628422-5	2020	In this study, we evaluated the influence of 11 single-nucleotide polymorphisms (SNPs) in CYP2B6, CYP2A6, CYP3A and ABCB1 (ATP-binding cassette sub-family B member 1) on the pharmacokinetics and safety of efavirenz after single oral dose administration to 47 healthy volunteers.	efavirenz	205-214	ATP binding cassette subfamily B member 1	Homo sapiens	116-121	
31628422-5	2020	In this study, we evaluated the influence of 11 single-nucleotide polymorphisms (SNPs) in CYP2B6, CYP2A6, CYP3A and ABCB1 (ATP-binding cassette sub-family B member 1) on the pharmacokinetics and safety of efavirenz after single oral dose administration to 47 healthy volunteers.	efavirenz	205-214	ATP binding cassette subfamily B member 1	Homo sapiens	123-165	
24497997-8	2014	RESULTS: EFV apparent clearance (CL/F) was 2.2 and 1.74 fold higher in CYP2B6*6 (*1/*1) and CYP2B6*6 (*1/*6) compared CYP2B6*6 (*6/*6) carriers, while a 22% increase in F1 was observed for carriers of ABCB1 c.4046A>G variant allele.	efavirenz	9-12	ATP binding cassette subfamily B member 1	Homo sapiens	201-206	
23133441-3	2012	The aim of the study was to evaluate the role of polymorphisms in ABCB1 gene on plasma efavirenz levels and treatment response in the form of change in viral load and CD-4 cell count in HIV/AIDS patients receiving efavirenz-containing highly active antiretroviral treatment regimens.	efavirenz	87-96	ATP binding cassette subfamily B member 1	Homo sapiens	66-71	
22297387-7	2012	Efavirenz (single dose) slightly increased ezetimibe absorption and markedly decreased exposure to ezetimibe-glucuronide (single dose and multiple dose), which may be explained by inhibition of UGT1A1 and ABCB1 (in vitro data).	efavirenz	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	205-210	
20660679-2	2010	In vitro data indicate that efavirenz induces several ATP-binding cassette (ABC) transporters, and pharmacogenetic studies found an association between ABCB1(C3435T) and efavirenz exposure and between this polymorphism and improved virological outcomes.	efavirenz	28-37	ATP binding cassette subfamily B member 1	Homo sapiens	152-157